LY3410738

LY3410738 · Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for LY3410738, covering 2025-06-27 to 2026-04-22. Get the full timeline:

Most recent: Clinical Trial Update: Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations [Phase 1]